BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

BioVie announced that data abstracts from its Phase 2 trials evaluating NE3107 in degenerative dementias and Parkinson's disease will be presented at the 2023 American Academy of Neurology Annual Meeting, being held virtually and in Boston, Massachusetts from April 22 to 27. The company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB which lead to neuroinflammation and insulin resistance in neurodegenerative disease without impacting their homeostatic functions such as insulin signalling and neuron growth and survival, according to BioVie.

BioVie to present Phase 2 trial data abstracts at 2023 American Academy of Neurology Annual Meeting

CARSON CITY, Nev., April 17, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data abstracts from its Phase 2 trials evaluating NE7107 in degenerative dementias and Parkinson's Disease will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, to be held virtually and in Boston, MA, April 22-27, 2023.

BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023

Seven months separate BioVie investors from Phase 3 results in Alzheimer's disease. During BioVie Day, the company announced six upcoming Phase 3 trials in Alzheimer's, Parkinson's, MCI and ascites.

BioVie Day And The Path Of Least Resistance To Approval In Alzheimer's

ORLANDO, FL / ACCESSWIRE / March 24, 2023 / RedChip Companies will air new interviews with BioVie Inc. (NASDAQ:BIVI) and iRemedy on The RedChip Money Report® on Bloomberg TV, this Saturday, March 25, at 7 p.m. Eastern Time (ET).

BioVie Inc. and iRemedy Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

CARSON CITY, Nev., March 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from its Phase 2 Parkinson's Disease (PD) trial will be presented at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2023) , to be held March 28 – April 1, 2023 in Gothenburg, Sweden.

BioVie Announces Data from Phase 2 Parkinson's Disease Trial Accepted for Presentation at AD/PD 2023

BioVie's stock has moved up considerably over the past 9 months in light of promising Alzheimer's data. BioVie Day and full Phase 2 Parkinson's trial results are scheduled for this month.

BioVie: Update On Alzheimer's And Parkinson's Programs, And Focus On Its Treatment For Refractory Ascites

Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time

BioVie Announces Registration Details for "BioVie Day" Webinar

BioVie Inc (NASDAQ:BIVI) revealed that it had paused patient enrollment in its Phase 2b clinical trial evaluating BIV201 for the treatment of refractory ascites after seeing encouraging data from the first 15 patients in the study. Ascites is a common complication of advanced liver cirrhosis involving the large accumulation of fluid in the abdomen, often exceeding 5 liters, due to liver and kidney dysfunction.

BioVie pauses patient enrollment in BIV201's Phase 2b trial for ascites after positive data; initiates FDA discussions on pivotal Phase 3 trial

Patients treated with BIV201 experienced reduced ascites fluid buildup (p

BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial

BioVie doesn't have any marketed therapies yet. The company lost $15.6 million in the fourth quarter.

Why Shares of BioVie Jumped This Week

CARSON CITY, Nev., March 09, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the participation of its management team in the Oppenheimer 33rd Annual Healthcare Conference, to be held virtually March 13-15, 2023.

BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference

BioVie Inc (NASDAQ:BIVI) has announced additional preliminary findings from the Parkinson's disease Phase 2 trial of its drug NE3107, showing a significant improvement over the current standard of care (SOC).  The preliminary findings show that significantly more patients treated with NE3107 were considered to be in what's called the “on” state of muscle control in the morning after withholding their usual (SOC) for at least 8 hours before taking their usual morning Parkinson's medications when compared to a placebo.

BioVie's drug NE3107 shown to help patients with muscle control in Parkinson's disease Phase 2 trial

6 out of 20 patients treated with NE3107 experienced a morning “on state” while 0 out of 19 placebo-treated patients had an “on” (p=0.02) 6 out of 20 patients treated with NE3107 experienced a morning “on state” while 0 out of 19 placebo-treated patients had an “on” (p=0.02)

BioVie Announces Additional Findings from Phase 2 Parkinson's Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo

The company is forging ahead with a phase 3 trial for its lead therapy.

Why Shares of BioVie Jumped 51.7% in February

BioVie Chief Medical Officer Dr. Joe Palumbo joins Natalie Stoberman from the Proactive studios to share more details behind the biotech company's work on Parkinson's, Alzheimer's and Cirrhosis treatments.

BioVie shares new insight behind NE3107 molecule development and inhibiting inflammation

BioVie Inc (NASDAQ:BIVI) said its NM101 trial evaluating NE3107 in the treatment of patients with Alzheimer's Disease has achieved its revised enrollment target of 400 patients, with top-line results from the study expected to be announced in October 2023. The company noted that the NM101 trial is a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028).

BioVie announces completion of patient enrollment in Phase 3 trial assessing NE3107 in Alzheimer's

Top Line Results Anticipated in October 2023 Top Line Results Anticipated in October 2023

BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer's Disease

CARSON CITY, Nev., Feb. 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that BioVie Day will be held March 23, 2023 at 10 a.m. Eastern Standard Time.

BioVie Announces “BioVie Day” to be held March 23, 2023

BioVie came out with phase 2 data in December. BIVI stock went up a lot, then fell equally badly, after that.

BioVie: Quick Rise And Fall Of An Alzheimer's Disease Drug Developer

BioVie's pipeline indications represent a combined addressable market size of more than $100 billion with high unmet medical needs. Phase 2 trials have provided evidence to indicate that NE3107 may improve cognition and function in Alzheimer's disease and dementia and may enhance motor control in Parkinson's disease.

BioVie Inc: A Catalyst-Rich Year Ahead

The biotech announced positive news from a pair of phase 2 clinical trials.

Why Shares of BioVie Rose 15.3% in December

ORLANDO, FL / ACCESSWIRE / December 29, 2022 / RedChip Companies will air a new interview BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, on The RedChip Money Report® on Bloomberg TV, this Saturday, Dec. 31, at 7 p.m. Eastern Time (ET).

BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in BioVie Inc. (BIVI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does BioVie Inc. (BIVI) Have the Potential to Rally 52% as Wall Street Analysts Expect?

Over the past few months, BioVie has reported good data from a Phase 2 trial in Alzheimer's and a Phase 2 placebo-controlled Parkinson's disease trial. The Phase 3 trial in Alzheimer's is ongoing.

BioVie: 9 Reasons For Enthusiasm

NEW YORK, NY / ACCESSWIRE / December 13, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with BioVie. Toni had the pleasure of recently conducting the Interview with Cuong Do, President & CEO BioVie Inc. (NASDAQ:BIVI).

News for BioVie Inc Stock (BIVI)